Danish biotech Pharmacosmos has come a long way since it was launched back in 1965 as an active pharmaceutical ingredient (API) manufacturer. While it’s still in the same family, the company now has three drugs approved to treat iron deficiency in humans (and a fourth for piglets).
BOSTON, Feb. 23, 2021 /PRNewswire/ -- AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).
HARWELL, England, Feb. 17, 2021 /PRNewswire/ -- AbFero Ltd., a subsidiary of AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).
HARWELL, England, Dec. 1, 2020 /PRNewswire/ -- AbFero Ltd., a subsidiary of AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron chelating compounds including their lead agent, SP-420, as a disease modifying therapy for Parkinson's disease.